Skip to main content
Springer Nature Link
Log in

The expression of Galectin-3 in breast cancer and its association with metastatic disease: a systematic review of the literature

  • Review
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Breast cancer is the most common form of cancer and the second highest cause of cancer mortality in female patients. The significance of the expression of Galectin-3 has been correlated with various malignancy types and in data from several research papers, the expression of Galectin-3 has been associated with the progression and metastasis of breast cancer. In the present study, the authors’ goal is to identify whether the expression of Galectin-3 in breast cancer can be associated with the presence and/or recurrence of a metastatic disease. Both Scopus and PubMed databases were utilized, by inputting the following combination of keywords: (((Breast) AND Metastasis)) AND ((Galectin 3) OR Galectin-3). The time of publication and text availability were not considered when searching the databases and all relevant articles in English were initially accepted. We included one case-control study, three retrospective case studies and one retrospective cohort study. In two of the included studies, the levels in concentration of Galectin-3 were not correlated with a significant difference in prognosis. In two studies, the lacking in expression of Galectin-3 was associated with a worse prognosis and in one of the studies selected, the elevated levels of Galectin-3 were correlated with recurrence of disease in triple negative breast cancer cases. For most of the studies selected for this review, the results were contradictory in regard to the role of Galectin-3 for prognosis and metastatic potential in female breast cancer patients. It is still unclear, whether Galectin-3 can be used as a prognostic marker for advanced breast cancer disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5(1):29–41

    Article  CAS  Google Scholar 

  2. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T et al (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76(4):597–598

    Article  CAS  Google Scholar 

  3. Takenaka Y, Fukumori T, Raz A (2002) Galectin-3 and metastasis. Glycoconj J 19(7–9):543–549

    Article  CAS  Google Scholar 

  4. Yang RY, Liu FT (2003) Galectins in cell growth and apoptosis. Cell Mol Life Sci 60(2):267–276

    Article  CAS  Google Scholar 

  5. Boutas I, Potiris A, Brenner W, Lebrecht A, Hasenburg A, Kalantaridou S et al (2019) The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature. Arch Gynecol Obstet 300(5):1113–1120

    Article  CAS  Google Scholar 

  6. Gillenwater A, Xu XC (1996) el-Naggar AK, Clayman GL, Lotan R. expression of galectins in head and neck squamous cell carcinoma. Head Neck 18(5):422–432

    Article  CAS  Google Scholar 

  7. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S et al (2007) Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 27(4B):2289–2296

    CAS  PubMed  Google Scholar 

  8. Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D (2008) Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 19(2):92–96

    Article  Google Scholar 

  9. Kim SJ, Shin JY, Cheong TC, Choi IJ, Lee YS, Park SH et al (2011) Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. Clin Exp Metastasis 28(8):743–750

    Article  CAS  Google Scholar 

  10. Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY et al (2006) Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 5(10):2727–2742

    Article  CAS  Google Scholar 

  11. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A (2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165(6):1931–1941

    Article  CAS  Google Scholar 

  12. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43–48

    Article  CAS  Google Scholar 

  13. Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–1290

    CAS  PubMed  Google Scholar 

  14. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D et al (2013) Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 4(4):542–549

    Article  Google Scholar 

  15. Eliaz I (2013) The role of Galectin-3 as a marker of Cancer and inflammation in a stage IV ovarian Cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol 6(2):343–349

    Article  Google Scholar 

  16. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin

  17. Honjo Y, Nangia-Makker P, Inohara H, Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7(3):661–668

    CAS  PubMed  Google Scholar 

  18. Song YK, Billiar TR, Lee YJ (2002) Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–1075

    Article  CAS  Google Scholar 

  19. Topcu TO, Kavgaci H, Gunaldi M, Kocoglu H, Akyol M, Mentese A et al (2018) The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis. J Cancer Res Ther 14(Supplement):S583–S5S6

    PubMed  Google Scholar 

  20. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q et al (2011) Serum galectin-2, −4, and −8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17(22):7035–7046

    Article  CAS  Google Scholar 

  21. Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T et al (2013) Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today 43(8):901–905

    Article  CAS  Google Scholar 

  22. Fernandez-Aguilar S, Noel JC (2008) Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS 116(1):33–40

    Article  Google Scholar 

  23. Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y (2016) Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget 7(14):18183–18203

    Article  Google Scholar 

  24. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30

    Article  Google Scholar 

  25. Fiorica JV (2016) Breast Cancer screening, mammography, and other modalities. Clin Obstet Gynecol 59(4):688–709

    Article  Google Scholar 

  26. Mayoral MA, Mayoral C, Meneses A, Villalvazo L, Guzman A, Espinosa B et al (2008) Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Investig 26(6):615–623

    Article  CAS  Google Scholar 

  27. Moisa A, Fritz P, Eck A, Wehner HD, Murdter T, Simon W et al (2007) Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 27(4B):2131–2139

    CAS  PubMed  Google Scholar 

  28. Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D (2016) Clinical significance of serum Galectin-3 levels in gastric Cancer patients. J Gastrointest Cancer 47(2):182–186

    Article  CAS  Google Scholar 

  29. Kataoka Y, Igarashi T, Ohshio Y, Fujita T, Hanaoka J (2019) Predictive importance of galectin-3 for recurrence of non-small cell lung cancer. Gen Thorac Cardiovasc Surg 67(8):704–711

    Article  Google Scholar 

  30. Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A et al (2015) Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol 21(1):47–50

    Article  Google Scholar 

  31. Funasaka T, Raz A, Nangia-Makker P (2014) Galectin-3 in angiogenesis and metastasis. Glycobiology 24(10):886–891

    Article  CAS  Google Scholar 

  32. Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA et al (2016) Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res 18(1):97

    Article  Google Scholar 

  33. Romero A, Gabius HJ (2019) Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target? Expert Opin Ther Targets 23(10):819–828

    Article  Google Scholar 

  34. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9(6):2374–2383

    CAS  PubMed  Google Scholar 

  35. Liu XH, Deng CX, Hu PC, Wang Y, Dong YH (2017) Functional impact of Galectin-3 and TRAIL expression in breast cancer cells. Eur Rev Med Pharmacol Sci 21(16):3626–3633

    PubMed  Google Scholar 

Download references

Funding

No funding has been granted for the study.

Author information

Author notes

  1. Ioannis Boutas and Anastasios Potiris contributed equally to this work.

Authors and Affiliations

  1. Third Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece

    Ioannis Boutas, Anastasios Potiris, Evangelos Makrakis, Pantelis Messaropoulos, Georgios-Konstantinos Papaioannou & Sophia Ν. Kalantaridou

Authors
  1. Ioannis Boutas
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Anastasios Potiris
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Evangelos Makrakis
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Pantelis Messaropoulos
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Georgios-Konstantinos Papaioannou
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Sophia Ν. Kalantaridou
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

I. Boutas and A. Potiris contributed equally to this work. IB: Project development, data collection and manuscript writing, AP: Project development, data collection and manuscript writing, EM: Manuscript editing, PM: Data review, GKP: Manuscript editing and SΝK: Project development, data review and manuscript editing.

Corresponding author

Correspondence to Anastasios Potiris.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent is not required for this type of study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boutas, I., Potiris, A., Makrakis, E. et al. The expression of Galectin-3 in breast cancer and its association with metastatic disease: a systematic review of the literature. Mol Biol Rep 48, 807–815 (2021). https://doi.org/10.1007/s11033-020-06122-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-020-06122-x

Keywords